





616.36  
L 68

AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES  
POSTGRADUATE COURSE 2003

# LIVER DISEASE IN THE 21ST CENTURY: Clinico-Pathologic Correlates

Course Directors Bruce R. Bacon, MD | Zachary D. Goodman, MD, PhD | Elizabeth M. Brunt, MD



*The Liver*  
BOSTON 2003  
*Meeting*

54<sup>th</sup> Annual Meeting of the  
American Association for  
the Study of Liver Diseases


**OCTOBER 24-25 2003**

John B. Hynes Convention Center  
Boston, Massachusetts

616,36  
L68

# LIVER DISEASE IN THE 21ST CENTURY: Clinico-Pathologic Correlates

Course Directors Bruce R. Bacon, MD | Zachary D. Goodman, MD, PhD | Elizabeth M. Brunt, MD



*The Liver*  
BOSTON 2003  
*Meeting*  
54th Annual Meeting of the  
American Association for  
the Study of Liver Diseases

761022  
Universitatea de Științe de  
Medicină și Farmacie  
«Nicolae Testemițanu» SL3  
Biblioteca Științifică Medicală

**OCTOBER 24-25 2003**

John B. Hynes Convention Center  
Boston, Massachusetts

# Table of Contents

Postgraduate Course Faculty . . . . .	5
Additional Meet-the-Professor Faculty . . . . .	7
Program . . . . .	9
Meet-the-Professor Luncheons . . . . .	13
Introduction . . . . .	19
<b>Fibrosis/Fibrogenesis</b>	
Pathologic Evaluation of Fibrosis . . . . .	23
<i>Zachary D. Goodman, MD, PhD</i>	
Mechanisms of Fibrogenesis . . . . .	32
<i>D. Montgomery Bissell, MD</i>	
Controversies in Fibrosis – Currently Available Strategies to Treat Fibrosis: We are getting closer . . . . .	41
<i>Don C. Rockey, MD</i>	
Controversies in Fibrosis – Currently Available Strategies to Treat Fibrosis: We have a long way to go. . . . .	43
<i>Timothy R. Morgan, MD</i>	
<b>Metals and the Liver</b>	
Pathology of Metal-Induced Liver Disease . . . . .	49
<i>Joel K. Greenson, MD</i>	
Mechanisms of Liver Injury and Fibrosis Due to Iron and Copper . . . . .	53
<i>Antonello Pietrangelo, MD, PhD</i>	
Non-HFE-Linked Iron Overload . . . . .	59
<i>Paul C. Adams, MD</i>	
<b>Fatty Liver Disease</b>	
Pathologic Spectrum of Fatty Liver Disease. . . . .	65
<i>Elizabeth M. Brunt, MD</i>	
Mechanisms of Fatty Liver Disease. . . . .	75
<i>Geoffrey C. Farrell, MD</i>	
Controversies in NAFLD – Controversy 1-Steatosis and Hepatitis C: Prognostic Significance. . . . .	82
<i>Arthur J. McCullough, MD</i>	
Controversies in NAFLD – Controversy 1-Steatosis and Hepatitis C: Response to Therapy . . . . .	88
<i>John G. McHutchison, MD</i>	
Controversies in NAFLD – Controversy 2-Clinical Utility of Liver Biopsy in NAFLD Pro. . . . .	90
<i>Brent A. Tetri, MD</i>	
Controversies in NAFLD – Controversy 2-Clinical Utility of Liver Biopsy in NAFLD Con . . . . .	93
<i>Stephen H. Caldwell, MD</i>	
<b>Viral Hepatitis</b>	
Viral Hepatitis as a Pre-malignant Disease: Dysplastic Lesions. . . . .	97
<i>Tania Roskams, MD, PhD</i>	
Screening for Hepatocellular Carcinoma in Chronic Hepatitis . . . . .	103
<i>Morris Sherman, MD, PhD</i>	
Role of Liver Biopsy in Post-transplant Hepatitis C. . . . .	111
<i>Stefan G. Hübscher, MD</i>	

Controversies in Viral Hepatitis – Is Liver Biopsy Always Necessary Before Treating Chronic Hepatitis B or C?	
Yes . . . . .	119
<i>Mitchell L. Shiffman, MD</i>	
Controversies in Viral Hepatitis – Is Liver Biopsy Always Necessary Before Treating Chronic Hepatitis B or C?	
No . . . . .	123
<i>Emmet B. Keeffe, MD</i>	
<b>Developmental Liver Diseases</b>	
Pathology of Developmental Anomalies of the Liver . . . . .	131
<i>Milton J. Finegold, MD</i>	
What Every Hepatologist Needs to Know About Pediatric Liver Disease . . . . .	143
<i>William F. Balistreri, MD</i>	
<b>Immune-Mediated Liver Diseases</b>	
Spectrum of Pathology . . . . .	159
<i>A. Brian West, MD</i>	
Primary Biliary Cirrhosis: Clinical Spectrum and Mechanisms of Disease . . . . .	168
<i>Keith D. Lindor, MD</i>	
Primary Sclerosing Cholangitis and Cholangiocarcinoma . . . . .	172
<i>Kirsten Muri Boberg, MD, PhD</i>	
Controversy: Treatment of Autoimmune Hepatitis and Overlap Syndromes	
Treatment Forever-Don't Take Any Chances . . . . .	178
<i>E. Jenny Heathcote, MD</i>	
Controversy: Treatment of Autoimmune Hepatitis and Overlap Syndromes	
Treatment Withdrawal-Dare to Relapse . . . . .	180
<i>Albert J. Czaja, MD</i>	
<b>Vascular Diseases of the Liver</b>	
Pathology of Vascular Diseases of the Liver . . . . .	187
<i>James M. Crawford, MD, PhD</i>	
Imaging of Vascular Liver Disease and Portal Hypertension . . . . .	199
<i>Steven G. Meranze, MD</i>	
Diagnosis-Putting it All Together . . . . .	204
<i>Thomas D. Boyer, MD</i>	
<b>Drug Hepatotoxicity</b>	
Pathologic Spectrum of Hepatotoxic Reactions . . . . .	211
<i>Kamal G. Ishak, MD, PhD</i>	
Pathogenesis and Diagnosis of Drug Toxicity . . . . .	220
<i>Neil Kaplowitz, MD</i>	
Acute Liver Failure-Role of Drugs . . . . .	224
<i>William M. Lee, MD</i>	
<b>Role of Liver Biopsy in 2003</b>	
Controversies in Liver Biopsy . . . . .	233
<i>Lawrence S. Friedman, MD</i>	
<b>Clinico-Pathological Correlation – CPC “Case”</b>	
Clinician	
<i>Adrian M. DiBisceglie, MD</i>	
Pathologist . . . . .	241
<i>Jay H. Lefkowitz, MD</i>	